Ad-SGE-REIC / Momotaro-Gene - LARVOL DELTA

Combination of bevacizumab enhances the anti-tumor efficacy of Ad-SGE-REIC for glioma (SNO 2024) - "These results suggest that the combination therapy of Ad-SGE-REIC and bevacizumab showed anti-glioma effects by suppressing the angiogenesis and invasion of tumor cells. Combined Ad-SGE-REIC and bevacizumab might be a promising strategy for the treatment of malignant glioma."

Clinical • Brain Cancer • CNS Tumor • Glioma • Malignant Glioma • Oncology • Solid Tumor • CTNNB1 • DKK3

PD-1 blockade augments CD8 T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer. (PubMed, Lung Cancer) - "Ad-SGE-REIC induced systemic antitumor immunity by modifying the TME status from non-inflamed to inflamed, with infiltration of CD8 T cells. Additionally, in Egfr-mutant lung cancer, this effect was enhanced by PD-1 blockade. These findings pave the way to establish a novel combined immunotherapy strategy with Ad-SGE-REIC and anti-PD-1 antibody for lung cancer with a non-inflamed TME."

IO biomarker • Journal • Gene Therapies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Transplantation • CD8 • DKK3 • EGFR

Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis. (PubMed, PLoS One) - "These results suggest that the combination therapy of Ad-SGE-REIC and bevacizumab exerts anti-glioma effects by suppressing the angiogenesis and invasion of tumors. Combined Ad-SGE-REIC and bevacizumab might be a promising strategy for the treatment of malignant glioma."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • CTNNB1 • DKK3

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: Momotaro-Gene Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2021 ➔ Jan 2023 | Trial primary completion date: Sep 2020 ➔ Dec 2022

Combination therapy • Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Solid Tumor

Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading. (PubMed, Front Oncol) - "An immune monitoring study was conducted using the serum samples on an adenovirus-mediated REIC/Dkk-3 gene therapy clinical trial that showed a successful clinical response in metastatic castration-resistant prostate cancer...Thus, quantitative monitoring of anti-CTA antibody biomarkers can be used to evaluate the cancer-immunity cycle. A quality-certified serum autoantibody monitoring system is a powerful tool for developing and evaluating cancer immunotherapy."

IO biomarker • Journal • Gene Therapies • Genito-urinary Cancer • Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • DKK3

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - P1/2; N=28; Completed; Sponsor: Momotaro-Gene Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Dkk3/REIC, an N-glycosylated Protein, Is a Physiological Endoplasmic Reticulum Stress Inducer in the Mouse Adrenal Gland. (PubMed, Acta Med Okayama) - "Forced expression of Dkk3 resulted in the induction of distinct levels of reporter expression, showing the UPR initiated by the ER membrane proteins of activating transcription factor 6 (ATF6) and inositol-requring enzyme 1 (IRE1). Thus, it is possible that Dkk3 is a physiological ER stressor in the mouse adrenal gland."

Journal • Preclinical • ATF6 • ERN1

Study protocol of a Phase I/IIa clinical trial of Ad-SGE-REIC for treatment of recurrent malignant glioma. (PubMed, Future Oncol) - "The secondary end points are the objective response rate and immunological assessment. Use of Ad-SGE-REIC will help to improve the prognosis of patients with malignant brain tumors."

Clinical • Journal • P1/2 data • Brain Cancer • Gene Therapies • Glioma • Oncology • Solid Tumor

Exogenous DKK-3/REIC inhibits Wnt/β-catenin signaling and cell proliferation in human kidney cancer KPK1. (PubMed, Oncol Lett) - "These findings indicate that exogenous DKK-3 upregulates p-β-catenin and inhibits Wnt/β-catenin signaling in an LRP6-independent manner. Therefore, exogenous DKK-3 protein may inhibit the proliferation of KPK1 cells via inactivating Wnt/β-catenin signaling."

Journal • Biosimilar • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer

NOVEL AD-REIC VECTOR WITH THE SUPER GENE EXPRESSION (SGE) SYSTEM (AD-SGE-REIC) AS A PROMISING THERAPEUTIC AGENT FOR MALIGNANT GLIOMA (SNO 2018) - "We demonstrated the anti-glioma effect of Ad-SGE-REIC. We are now planning an investigator-initiated clinical trial (phase I/IIa) of Ad-SGE-REIC for the treatment of recurrent malignant glioma."

Brain Cancer • Oncology • Solid Tumor

Promising gene therapy using an adenovirus vector carrying REIC/Dkk-3 gene for the treatment of biliary cancer. (PubMed, Curr Gene Ther) - "Ad-SGE-REIC induced apoptosis and inhibited tumor growth in biliary cancer cells. REIC/Dkk-3 gene therapy using Ad-SGE-REIC is an attractive therapeutic tool for biliary cancer."

Journal • MAPK8

The current status of Ad-SGE-REIC gene therapy for malignant glioma (SNO 2019) - "We demonstrated the anti-glioma effect of Ad-SGE-REIC. We will start a phase I/IIa clinical trial of Ad-SGE-REIC for the treatment of recurrent malignant glioma."

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - P1/2; N=28; Active, not recruiting; Sponsor: Momotaro-Gene Inc.; Trial completion date: Jun 2019 ➔ Mar 2020

Clinical • Trial completion date

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer (clinicaltrials.gov) - P1/2; N=28; Active, not recruiting; Sponsor: Momotaro-Gene Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2018 ➔ Jun 2019

Clinical • Enrollment closed • Trial completion date